Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 377, Issue 1, 2008, Pages 65-76

  Bilkei Gorzo, Andras ^a   Abo Salem, Osama M ^a,b   Hayallah, Alaa M ^a,c   Michel, Kerstin ^a   Müller, Christa E ^a   Zimmer, Andreas ^a  

^a UNIVERSITY OF BONN   (Germany)

^b AL AZHAR UNIVERSITY   (Egypt)

^c Assiut University   (Egypt)

Author keywords

A 3; A1; A2A; A2B; Adenosine receptors; Antagonist; Carrageenan; Edema; Formalin; Hyperalgesia; Inflammatory pain

Indexed keywords

1 BUTYL 8 (3 NORADAMANTANYL) 3 (3 HYDROXYPROPYL)XANTHINE; 1 PROPYL 8 (4 SULFOPHENYL)XANTHINE; 8 ETHYL 4 METHYL 2 (2,3,5 TRICHLOROPHENYL) 4,5,7,8 TETRAHYDRO 1H IMIDAZO[2,1 I]PURIN 5 ONE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; CARRAGEENAN; FORMALDEHYDE; MSX 3; PHOSPHORIC ACID MONO[3 [8 [2 (3 METHOXYPHENYL)VINYL] 7 METHYL 2,6 DIOXO 1 PROP 2 YNYL 1,2,6,7 TETRAHYDROPURIN 3 YL]PROPYL]ESTER; PSB 10; PSB 1115; PSB 36; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENCY; DRUG SELECTIVITY; EDEMA; HYPERALGESIA; INFLAMMATION; MALE; MOUSE; NONHUMAN; PAIN ASSESSMENT; RECEPTOR BLOCKING; SYSTEMIC THERAPY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE MODELS, ANIMAL; EDEMA; HYPERALGESIA; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR STRUCTURE; PAIN; PROTEIN SUBUNITS; RECEPTORS, PURINERGIC P1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 39149142810     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0252-9     Document Type: Article

References (80)

1. Abo-Salem OM, Hayallah AM, Bilkei-Gorzo A, Filipek B, Zimmer A, Muller CE (2004) Antinociceptive effects of novel A2B adenosine receptor antagonists. J Pharmacol Exp Ther 308:358-366
2. Akkari R, Burbiel JC, Hockemeyer J, Muller CE (2006) Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr Top Med Chem 6:1375-1399
3. Antonioli L, Fornai M, Colucci R, Ghisu N, Da Settimo F, Natale G, Kastsiuchenka O, Duranti E, Virdis A, Vassalle C, La Motta C, Mugnaini L, Breschi MC, Blandizzi C, Del Taca M (2007) Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J Pharmacol Exp Ther 322:435-442
4. Auchampach JA, Jin X, Wan TC, Caughey GH, Linden J (1997) Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. Mol Pharmacol 52:846-860
5. Bookser BC, Ugarkar BG, Matelich MC, Lemus RH, Allan M, Tsuchiya M, Nakane M, Nagahisa A, Wiesner JB, Erion MD (2005) Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-d-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides and related compounds. J Med Chem 48:7808-7820
6. Boughton-Smith NK, Deakin AM, Follenfant RL, Whittle BJ, Garland LG (1993) Role of oxygen radicals and arachidonic acid metabolites in the reverse passive Arthus reaction and carrageenin paw oedema in the rat. Br J Pharmacol 110:896-902
7. Boyer SH, Ugarkar BG, Solbach J, Kopcho J, Matelich MC, Ollis K, Gomez-Galeno JE, Mendonca R, Tsuchiya M, Nagahisa A, Nakane M, Wiesner JB, Erion MD (2005) Adenosine kinase inhibitors. 5. Synthesis, enzyme inhibition, and analgesic activity of diaryl-erythro-furanosyltubercidin analogues. J Med Chem 48:6430-6441
8. Cadieux JS, Leclerc P, St-Onge M, Dussault AA, Laflamme C, Picard S, Ledent C, Borgeat P, Pouliot M (2005) Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal. J Cell Sci 118:1437-1447
9. Day YJ, Huang L, Ye H, Li L, Linden J, Okusa MD (2006) Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol 176:3108-3114
10. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC (1996) Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118:1461-1468
11. Dowd E, McQueen DS, Chessell IP, Humphrey PP (1998) Adenosine A1 receptor-mediated excitation of nociceptive afferents innervating the normal and arthritic rat knee joint. Br J Pharmacol 125:1267-1271
12. Esquisatto LC, Costa SK, Camargo EA, Ribela MT, Brain SD, de Nucci G, Antunes E (2001) The plasma protein extravasation induced by adenosine and its analogues in the rat dorsal skin: evidence for the involvement of capsaicin sensitive primary afferent neurones and mast cells. Br J Pharmacol 134:108-115
13. Feoktistov I, Biaggioni I (1996) Role of adenosine in asthma. Drug Dev Res 39:333-336
14. Fiebich BL, Biber K, Gyufko K, Berger M, Bauer J, van Calker D (1996a) Adenosine A2b receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells. J Neurochem 66:1426-1431
15. Fiebich BL, Biber K, Lieb K, van Calker D, Berger M, Bauer J, Gebicke-Haerter PJ (1996b) Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 18:152-160
16. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552
17. Hasko G, Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. Trends Immunol 25:33-39
18. Hockemeyer J, Burbiel JC, Muller CE (2004) Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J Org Chem 69:3308-3318
19. Honore P, Buritova J, Chapman V, Besson JM (1998) UP 202-56, an adenosine analogue, selectively acts via A1 receptors to significantly decrease noxiously-evoked spinal c-Fos protein expression. Pain 75:281-293
20. Jacker HJ, Richter J (1975) Possibilities and limitations of the use of rat paw edemas as models of inflammation. 1. Review on edemas as models and their possible use. Pharmazie 30:417-422
21. Jacobson KA (1998) Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 19:184-191
22. Jarvis MF, Yu H, McGaraughty S, Wismer CT, Mikusa J, Zhu C, Chu K, Kohlhaas K, Cowart M, Lee CH, Stewart AO, Cox BF, Polakowski J, Kowaluk EA (2002) Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor. Pain 96:107-118
23. Kalda A, Yu L, Oztas E, Chen JF (2006) Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. J Neurol Sci 248:9-15
24. Karlsten R, Gordh T, Post C (1992) Local antinociceptive and hyperalgesic effects in the formalin test after peripheral administration of adenosine analogues in mice. Pharmacol Toxicol 70:434-438
25. Kolachala V, Asamoah V, Wang L, Obertone TS, Ziegler TR, Merlin D, Sitaraman SV (2005) TNF-alpha upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: a basis for A2bR overexpression in colitis. Cell Mol Life Sci 62:2647-2657
26. Konig M, Zimmer AM, Steiner H, Holmes PV, Crawley JN, Brownstein MJ, Zimmer A (1996) Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383:535-538
27. Kowaluk EA, Jarvis MF (2000) Therapeutic potential of adenosine kinase inhibitors. Expert Opin Investig Drugs 9:551-564
28. Kowaluk EA, Kohlhaas KL, Bannon A, Gunther K, Lynch JJ 3rd, Jarvis MF (1999) Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice. Pharmacol Biochem Behav 63:83-91
29. Kowaluk EA, Mikusa J, Wismer CT, Zhu CZ, Schweitzer E, Lynch JJ, Lee CH, Jiang M, Bhagwat SS, Gomtsyan A, McKie J, Cox BF, Polakowski J, Reinhart G, Williams M, Jarvis MF (2000) ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino- pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. J Pharmacol Exp Ther 295:1165-1174
30. Kuno M, Seki N, Tsujimoto S, Nakanishi I, Kinoshita T, Nakamura K, Terasaka T, Nishio N, Sato A, Fujii T (2006) Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938. Eur J Pharmacol 534:241-249
31. Lappas CM, Sullivan GW, Linden J (2005) Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin Investig Drugs 14:797-806
32. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M (1997) Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388:674-678
33. Li X, Conklin D, Ma W, Zhu X, Eisenach JC (2002) Spinal noradrenergic activation mediates allodynia reduction from an allosteric adenosine modulator in a rat model of neuropathic pain. Pain 97:117-125
34. Linden J (2001) Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41:775-787
35. Livingston M, Heaney LG, Ennis M (2004) Adenosine, inflammation and asthma-a review. Inflamm Res 53:171-178
36. Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M (2004) Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol 173:21-24
37. Marx D, Ezeamuzie CI, Nieber K, Szelenyi I (2001) Therapy of bronchial asthma with adenosine receptor agonists or antagonists. Drug News Perspect 14:89-100
38. McGaraughty S, Cowart M, Jarvis MF (2001) Recent developments in the discovery of novel adenosine kinase inhibitors: mechanism of action and therapeutic potential. CNS Drug Rev 7:415-432
39. McGaraughty S, Cowart M, Jarvis MF, Berman RF (2005) Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr Top Med Chem 5:43-58
40. Muller CE (2003) Medicinal chemistry of adenosine A3 receptor ligands. Curr Top Med Chem 3:445-462
41. Muller CE, Ferre S (2007) Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. Rec Patents CNS Drug Discov 2:1-21
42. Mustafa SJ, Nadeem A, Fan M, Zhong H, Belardinelli L, Zeng D (2007) Effect of a specific and selective A(2B) adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther 320:1246-1251
43. Nadeem A, Obiefuna PC, Wilson CN, Mustafa SJ (2006) Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation. Eur J Pharmacol 551:116-124
44. Nadeem A, Fan M, Ansari HR, Ledent C, Mustafa SJ (2007) Enhanced airway reactivity and inflammation in A2A adenosine receptor deficient allergic mice. Am J Physiol Lung Cell Mol Physiol 292(6):L1335-L1344
45. Nakamura I, Ohta Y, Kemmotsu O (1997) Characterization of adenosine receptors mediating spinal sensory transmission related to nociceptive information in the rat. Anesthesiology 87:577-584
46. Odashima M, Bamias G, Rivera-Nieves J, Linden J, Nast CC, Moskaluk CA, Marini M, Sugawara K, Kozaiwa K, Otaka M, Watanabe S, Cominelli F (2005) Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 129:26-33
47. Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916-920
48. Ongini E, Fredholm BB (1996) Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci 17:364-372
49. Ozola V, Thorand M, Diekmann M, Qurishi R, Schumacher B, Jacobson KA, Müller CE (2003) 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at human A3 adenosine receptors. Bioorg Med Chem 11:347-356
50. Poon A, Sawynok J (1998) Antinociception by adenosine analogs and inhibitors of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat. Pain 74:235-245
51. Poon A, Sawynok J (1999) Antinociceptive and anti-inflammatory properties of an adenosine kinase inhibitor and an adenosine deaminase inhibitor. Eur J Pharmacol 384:123-138
52. Posadas I, Bucci M, Roviezzo F, Rossi A, Parente L, Sautebin L, Cirino G (2004) Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression. Br J Pharmacol 142:331-338
53. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492
54. Ramkumar V, Stiles GL, Beaven MA, Ali H (1993) The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 268:16887-16890
55. Ramkumar V, Hallam DM, Nie Z (2001) Adenosine, oxidative stress and cytoprotection. Jpn J Pharmacol 86:265-274
56. Ramos-Zepeda G, Schroder W, Rosenow S, Herrero JF (2004) Spinal vs. supraspinal antinociceptive activity of the adenosine A(1) receptor agonist cyclopentyl-adenosine in rats with inflammation. Eur J Pharmacol 499:247-256
57. Reeve AJ, Dickenson AH (1995) The roles of spinal adenosine receptors in the control of acute and more persistent nociceptive responses of dorsal horn neurones in the anaesthetized rat. Br J Pharmacol 116:2221-2228
58. Rosi S, McGann K, Hauss-Wegrzyniak B, Wenk GL (2003) The influence of brain inflammation upon neuronal adenosine A2B receptors. J Neurochem 86:220-227
59. Ryzhov SV, Zaynagetdinov R, Goldstein AE, Novitskiy SV, Blackburn MR, Biaggioni I, Feoktistov I (2007) Effect of A2B adenosine receptor gene ablation on adenosine-dependent regulation of pro-inflammatory cytokines. J Pharmacol Exp Ther (in press)
60. Salmon JE, Cronstein BN (1990) Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory. J Immunol 145:2235-2240
61. Sawynok J (1998) Adenosine receptor activation and nociception. Eur J Pharmacol 347:1-11
62. Sawynok J, Zarrindast MR, Reid AR, Doak GJ (1997) Adenosine A3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine. Eur J Pharmacol 333:1-7
63. Sawynok J, Reid A, Liu XJ (1999) Acute paw oedema induced by local injection of adenosine A(1), A(2) and A(3) receptor agonists. Eur J Pharmacol 386:253-261
64. Sawynok J, Reid A, Liu XJ (2000) Involvement of mast cells, sensory afferents and sympathetic mechanisms in paw oedema induced by adenosine A(1) and A(2B/3) receptor agonists. Eur J Pharmacol 395:47-50
65. Sullivan GW (2003) Adenosine A2A receptor agonists as anti-inflammatory agents. Curr Opin Investig Drugs 4:1313-1319
66. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, Blackburn MR (2006) Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 116:2173-2182
67. Terai T, Kusunoki T, Kita Y, Yoshida K, Akahane A, Shiokawa Y, Kohno Y, Horiai H, Mori J, Mine Y, Kohsaka M (1996) General pharmacology of the new non-xanthine adenosine A1 receptor antagonist (+)-(R)-[(E)-3-(2- phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-piperidine ethanol. Arzneimittelforschung 46:185-191
68. Thiel M, Caldwell CC, Sitkovsky MV (2003) The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect 5:515-526
69. Vinegar R, Truax JF, Selph JL (1976) Quantitative studies of the pathway to acute carrageenan inflammation. Fed Proc 35:2447-2456
70. Weyler S, Fulle F, Diekmann M, Schumacher B, Hinz S, Klotz KN, Muller CE (2006) Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones. ChemMedChem 1:891-902
71. Wu WP, Hao JX, Halldner-Henriksson L, Xu XJ, Jacobson MA, Wiesenfeld-Hallin Z, Fredholm BB (2002) Decreased inflammatory pain due to reduced carrageenan-induced inflammation in mice lacking adenosine A3 receptors. Neuroscience 114:523-527
72. Wu WP, Hao JX, Halldner L, Lovdahl C, DeLander GE, Wiesenfeld-Hallin Z, Fredholm BB, Xu XJ (2005) Increased nociceptive response in mice lacking the adenosine A1 receptor. Pain 113:395-404
73. Yan L, Muller CE (2004) Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability. J Med Chem 47:1031-1043
74. Yang Z, Day YJ, Toufektsian MC, Ramos SI, Marshall M, Wang XQ, French BA, Linden J (2005) Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 111:2190-2197
75. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K (2006) The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 116:1913-1923
76. Yang M, Soohoo D, Soelaiman S, Kalla R, Zablocki J, Chu N, Leung K, Yao L, Diamond I, Belardinelli L, Shryock JC (2007) Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 375:133-144
77. Young HW, Molina JG, Dimina D, Zhong H, Jacobson M, Chan LN, Chan TS, Lee JJ, Blackburn MR (2004) A3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J Immunol 173:1380-1389
78. Zablocki J, Elzein E, Kalla R (2006) A2B adenosine receptor antagonists and their potential indications. Exp Opin Ther Patents 16:1347-1357
79. Zhong H, Wu Y, Belardinelli L, Zeng D (2006) A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-alpha increase. Am J Respir Cell Mol Biol 35:587-592
80. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 96:5780-5785